23 related articles for article (PubMed ID: 23955138)
1. Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab).
De Luca R; Lo Coco G; Addeo R; Fattoruso SIS; Auriemma A; Paci R; Mistretta O; Epifanio MS; Salvato A; D'Agostino A; Cicero G
World J Oncol; 2021 Aug; 12(4):104-110. PubMed ID: 34349854
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study.
Suh Oh HJ; Flórez Menéndez Á; Sacristán Santos V; Fernández Ribeiro F; Vilanova-Trillo L; Constenla Figueiras M; Pereiro Ferreiros M
Drugs Context; 2020; 9():. PubMed ID: 32821263
[TBL] [Abstract][Full Text] [Related]
3. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study.
Lee J; Lim J; Park JS; Kim M; Kim TY; Kim TM; Lee KH; Keam B; Han SW; Mun JH; Cho KH; Jo SJ
Cancer Res Treat; 2018 Oct; 50(4):1186-1193. PubMed ID: 29237254
[TBL] [Abstract][Full Text] [Related]
5. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.
Tischer B; Huber R; Kraemer M; Lacouture ME
Support Care Cancer; 2017 Feb; 25(2):651-660. PubMed ID: 27718067
[TBL] [Abstract][Full Text] [Related]
6. Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials.
Koukakis R; Gatta F; Hechmati G; Siena S
Qual Life Res; 2016 Oct; 25(10):2645-2656. PubMed ID: 27083443
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.
Chan A; Cameron MC; Garden B; Boers-Doets CB; Schindler K; Epstein JB; Choi J; Beamer L; Roeland E; Russi EG; Bensadoun RJ; Teo YL; Chan RJ; Shih V; Bryce J; Raber-Durlacher J; Gerber PA; Freytes CO; Rapoport B; LeBoeuf N; Sibaud V; Lacouture ME
Support Care Cancer; 2015 Aug; 23(8):2231-44. PubMed ID: 25564221
[TBL] [Abstract][Full Text] [Related]
8. Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.
van de Watering FC; Rijpkema M; Perk L; Brinkmann U; Oyen WJ; Boerman OC
Biomed Res Int; 2014; 2014():203601. PubMed ID: 24991539
[TBL] [Abstract][Full Text] [Related]
9. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients.
Ra HS; Shin SJ; Kim JH; Lim H; Cho BC; Roh MR
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e53-9. PubMed ID: 22329482
[TBL] [Abstract][Full Text] [Related]
10. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer.
Kuboki Y; Matsusaka S; Minowa S; Shibata H; Suenaga M; Shinozaki E; Mizunuma N; Ueno M; Yamaguchi T; Hatake K
Anticancer Res; 2013 Sep; 33(9):3905-10. PubMed ID: 24023327
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic colorectal cancer with cetuximab: influence on the quality of life.
Unger K; Niehammer U; Hahn A; Goerdt S; Schumann M; Thum S; Schepp W
Z Gastroenterol; 2013 Aug; 51(8):733-9. PubMed ID: 23955138
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
14. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
Woo J; Palmisiano N; Tester W; Leighton JC
Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
[TBL] [Abstract][Full Text] [Related]
15. Relationships between quality of life and skin toxicities of epidermal growth factor receptor inhibitors in cancer patients: A literature review.
Hirayama K; Su Y; Chiba M; Izutsu M; Yuki M
Jpn J Nurs Sci; 2020 Jul; 17(3):e12321. PubMed ID: 31930679
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
